ReviewCanadian journal of gastroenterology = Journal canadien de gastroenterologie2009
A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.
Review in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.International journal of hematology · 2022Trial
- Eczematous Drug Eruptions.American journal of clinical dermatology · 2021Review
- Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.Journal of the American Academy of Dermatology · 2020Review
- Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents.World journal of hepatology · 2018Article
- A case of erythrodermia from exacerbated psoriasis vulgaris due to treatment of acute hepatitis C.BMC dermatology · 2016Article
- Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy.Hepatitis monthly · 2015Article
- Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C.Journal of dermatological case reports · 2014Article
- New treatments for chronic hepatitis C: an overview for paediatricians.World journal of gastroenterology · 2014Review
- Skin Adverse Events During Dual and Triple Therapy for HCV-Related Cirrhosis.Hepatitis monthly · 2014Article
- Peginterferon alfa related psoriasis in a patient with acute hepatitis C and review of the literature.Wiener klinische Wochenschrift · 2013Review
- Erythema annulare centrifugum-like eruption associated with pegylated interferon treatment for hepatitis C.Dermatology reports · 2013Article
- Arenavirus reverse genetics for vaccine development.The Journal of general virology · 2013Article
- Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Review
- Arenavirus nucleoproteins prevent activation of nuclear factor kappa B.Journal of virology · 2012Article
- Psoriasis and hepatitis C: improvement with interferon.Annals of dermatology · 2011Article
- Eczema craquelé associated with antiviral treatment for chronic hepatitis C.Anais brasileiros de dermatologiaArticle
- Cutaneous Eruption due to Telaprevir.Case reports in dermatologyArticle
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced cutaneous eruptions are named among the most common side effects of many medications. Thus, cutaneous drug eruptions are a common cause of morbidity and mortality, especially in hospital settings. The present article reviews different presentations of drug-induced cutaneous eruptions, with a focus on eruptions reported secondary to the use of interferon and ribavirin. Presentations include injection site reactions, psoriasis, eczematous drug reactions, alopecia, sarcoidosis, lupus, fixed drug eruptions, pigmentary changes and lichenoid eruptions. Also reviewed are findings regarding life-threatening systemic drug reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.